Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05772520 · ClinicalTrials.gov registry record · Phase 2
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Hangzhou Highlightll Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT05772520 is a Phase 2 study of Plaque Psoriasis that has completed, run by Hangzhou Highlightll Pharmaceutical Co.. The registered enrollment target is 82 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05772520, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by Hangzhou Highlightll Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.
Conditions Studied
Interventions
- DRUG TLL018 tablets
Study Locations (20)
Florida
- Life Clinical Trials - Coral Springs
- Palm Beach - DeLand
- D&H Doral Research Center LLC - Doral
- Sweet Hope Research Specialty, Inc - Hialeah
- CNS - Jacksonville - Jacksonville
- CNS - Orlando SODO - Jacksonville
- Altus Research - Lake Worth
- Anchor Medical Research, LLC (Core Clinical Trials) - Miami
- Reserka Research - Miami
- ForCare Medical (CenExcel) - Tampa
California
- Moy, Fincher, Chipps - Beverly Hills
- Metropolis Derm - Los Angeles
- Amicis Research Center - Northridge
- Integrative Skin - Sacramento
- Skin Surgical - San Diego
Alabama
- Cahaba - Birmingham
Iowa
- Integrated Clinical Trial Services, Inc - Des Moines
Louisiana
- IMA Clinical Research - Monroe
Maryland
- Lawrence Green - Rockville
Massachusetts
- Metro Boston - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05772520
The ClinicalTrials.gov registry entry for NCT05772520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (80% lower). The listed sponsor is Hangzhou Highlightll Pharmaceutical Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which TLL018 tablets is the first listed.
NCT05772520 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05772520 about?
NCT05772520 is a clinical study titled "The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis". This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.
What is the current status of trial NCT05772520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2023-01-19. Estimated completion is 2024-12-23.
What conditions does trial NCT05772520 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05772520?
The interventions under investigation include: TLL018 tablets (DRUG).
Who is sponsoring clinical trial NCT05772520?
This trial is sponsored by Hangzhou Highlightll Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05772520 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.